πŸ‡ΊπŸ‡Έ FDA
Patent

US 11618888

Tumor-selective E1A and E1B mutants

granted A61KA61K35/761A61K48/00

Quick answer

US patent 11618888 (Tumor-selective E1A and E1B mutants) held by The Regents of the University of California expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K35/761, A61K48/00, A61P, A61P35/00